Literature DB >> 22127925

Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells.

Theresa Placke1, Melanie Örgel, Martin Schaller, Gundram Jung, Hans-Georg Rammensee, Hans-Georg Kopp, Helmut Rainer Salih.   

Abstract

Natural killer (NK) cells are cytotoxic lymphocytes that play an important role in tumor immunosurveillance, preferentially eliminating targets with low or absent expression of MHC class I and stress-induced expression of ligands for activating NK receptors. Platelets promote metastasis by protecting disseminating tumor cells from NK cell immunosurveillance, but the underlying mechanisms are not well understood. In this study, we show that tumor cells rapidly get coated in the presence of platelets in vitro, and circulating tumor cells of cancer patients display coexpression of platelet markers. Flow cytometry, immunofluorescent staining, confocal microscopy, and analyses on an ultrastructural level using immunoelectron microscopy revealed that such coating may cause transfer of MHC class I onto the tumor cell surface resulting in high-level expression of platelet-derived normal MHC class I. The resulting "phenotype of false pretenses" disrupts recognition of tumor cell missing self, thereby impairing cytotoxicity and IFN-γ production by NK cells. Thus, our data indicate that platelets, by conferring an unsuspicious "pseudonormal" phenotype, may enable a molecular mimicry that allows metastasizing tumor cells to downregulate MHC class I, to escape T-cell-mediated immunity without inducing susceptibility to NK cell reactivity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22127925     DOI: 10.1158/0008-5472.CAN-11-1872

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  129 in total

Review 1.  The Platelet Lifeline to Cancer: Challenges and Opportunities.

Authors:  Monika Haemmerle; Rebecca L Stone; David G Menter; Vahid Afshar-Kharghan; Anil K Sood
Journal:  Cancer Cell       Date:  2018-04-12       Impact factor: 31.743

2.  Genetic engineering of platelets to neutralize circulating tumor cells.

Authors:  Jiahe Li; Charles C Sharkey; Brittany Wun; Jane L Liesveld; Michael R King
Journal:  J Control Release       Date:  2016-02-26       Impact factor: 9.776

3.  Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles.

Authors:  Jiahe Li; Yiwei Ai; Lihua Wang; Pengcheng Bu; Charles C Sharkey; Qianhui Wu; Brittany Wun; Sweta Roy; Xiling Shen; Michael R King
Journal:  Biomaterials       Date:  2015-10-21       Impact factor: 12.479

4.  PF4 Promotes Platelet Production and Lung Cancer Growth.

Authors:  Ferdinando Pucci; Steffen Rickelt; Andita P Newton; Christopher Garris; Ernesto Nunes; Charles Evavold; Christina Pfirschke; Camilla Engblom; Mari Mino-Kenudson; Richard O Hynes; Ralph Weissleder; Mikael J Pittet
Journal:  Cell Rep       Date:  2016-11-08       Impact factor: 9.423

Review 5.  Molecular principles of metastasis: a hallmark of cancer revisited.

Authors:  Jawad Fares; Mohamad Y Fares; Hussein H Khachfe; Hamza A Salhab; Youssef Fares
Journal:  Signal Transduct Target Ther       Date:  2020-03-12

6.  Platelets promoting tumor metastasis: culprits or victims?

Authors:  Reinhard Buettner
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

7.  Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells.

Authors:  Stefanie Maurer; Korbinian Nepomuk Kropp; Gerd Klein; Alexander Steinle; Sebastian P Haen; Juliane S Walz; Clemens Hinterleitner; Melanie Märklin; Hans-Georg Kopp; Helmut Rainer Salih
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

Review 8.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

Review 9.  Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.

Authors:  Alexander David Barrow; Marco Colonna
Journal:  Semin Immunol       Date:  2017-09-19       Impact factor: 11.130

Review 10.  Metastasis review: from bench to bedside.

Authors:  Ali Mohammad Alizadeh; Sadaf Shiri; Sadaf Farsinejad
Journal:  Tumour Biol       Date:  2014-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.